Literature DB >> 24464489

Urologic agents for treatment of bladder dysfunction in neurologic disease.

Eliza Lamin1, Ariana L Smith.   

Abstract

OPINION STATEMENT: Bladder dysfunction, which is commonly associated with neurologic disorders, can present in myriad ways, from complete retention of urine to total urinary incontinence. The multiple options for treating neurogenic bladder dysfunction range from minimally invasive lifestyle changes to major surgical interventions. Interventions may be driven by patient-reported nuisance or by medical necessity, as in the case of impaired compliance with associated upper urinary tract compromise. Pharmacologic treatment has long been the mainstay in the management of bladder dysfunction, particularly for overactive bladder symptoms [1]. While there are many different medications for overactive bladder dysfunction, most are in the category of antimuscarinics. Each medication has a slightly different side effect profile, which may be important in the drug selection process [2]. When these are not tolerated or are ineffective, beta agonists, phosphodiesterase inhibitors, tricyclic antidepressants, and the gamma aminobutyric acid (GABA)-B agonist baclofen can be added or substituted. For difficulty emptying, alpha adrenergic antagonists can be used [3]. Intravesical options are also available for overactive bladder (OAB) symptoms. The most common is botulinum toxin, which works by decreasing the activity of the detrusor smooth muscle, thereby decreasing OAB symptoms [4]. Percutaneous nerve stimulation may also be used [5•].

Entities:  

Year:  2014        PMID: 24464489     DOI: 10.1007/s11940-013-0280-3

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  16 in total

1.  [What to do if percutaneous tibial nerve stimulation (PTNS) works? A pilot study on home-based transcutaneous tibial nerve stimulation].

Authors:  Valentina Maurelli; Filomena Petta; Gianni Carsillo; Roberto Miano; Fiorenza Lamorte; Claudio Perugia; Enrico Finazzi Agrò
Journal:  Urologia       Date:  2012-12-30

2.  Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.

Authors:  Nazema Y Siddiqui; Cindy L Amundsen; Anthony G Visco; Evan R Myers; Jennifer M Wu
Journal:  J Urol       Date:  2009-10-17       Impact factor: 7.450

Review 3.  Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis.

Authors:  Priya Madhuvrata; Manju Singh; Zaid Hasafa; Mohamed Abdel-Fattah
Journal:  Eur Urol       Date:  2012-02-25       Impact factor: 20.096

4.  Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.

Authors:  Brigitte Schurch; Marianne de Sèze; Pierre Denys; Emmanuel Chartier-Kastler; Francois Haab; Karel Everaert; Pierre Plante; Brigitte Perrouin-Verbe; Catherine Kumar; Stephanie Fraczek; Mitchell F Brin
Journal:  J Urol       Date:  2005-07       Impact factor: 7.450

5.  Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.

Authors:  Christopher R Chapple; Aino Fianu-Jonsson; Mark Indig; Vik Khullar; José Rosa; Roberto M Scarpa; Arun Mistry; D Mark Wright; John Bolodeoku
Journal:  Eur Urol       Date:  2007-06-06       Impact factor: 20.096

6.  Impact of fesoterodine on quality of life: pooled data from two randomized trials.

Authors:  Con J Kelleher; Andrea Tubaro; Joseph T Wang; Zoe Kopp
Journal:  BJU Int       Date:  2008-07       Impact factor: 5.588

7.  Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial.

Authors:  Bee Yean Low; Men Long Liong; Kah Hay Yuen; Christopher Chee; Wing Seng Leong; Wooi Loong Chong; Nurzalina Abdul Karim Khan; Phaik Yeong Cheah; Ker Keong Liong
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

8.  Combination drug therapy improves compliance of the neurogenic bladder.

Authors:  Anne P Cameron; J Quentin Clemens; Jerilyn M Latini; Edward J McGuire
Journal:  J Urol       Date:  2009-07-18       Impact factor: 7.450

9.  Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.

Authors:  Kenneth M Peters; Donna J Carrico; Leslie S Wooldridge; Christopher J Miller; Scott A MacDiarmid
Journal:  J Urol       Date:  2012-12-03       Impact factor: 7.450

10.  Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation.

Authors:  Melissa Martinson; Scott MacDiarmid; Edward Black
Journal:  J Urol       Date:  2012-11-20       Impact factor: 7.450

View more
  3 in total

Review 1.  Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients.

Authors:  Areeba Sadiq; Benjamin M Brucker
Journal:  Curr Urol Rep       Date:  2015-07       Impact factor: 3.092

Review 2.  Central role of the BK channel in urinary bladder smooth muscle physiology and pathophysiology.

Authors:  Georgi V Petkov
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-07-02       Impact factor: 3.619

3.  Serotonin and noradrenaline reuptake inhibitors improve micturition control in mice.

Authors:  Marco Redaelli; María Jimena Ricatti; Marialaura Simonetto; Mirko Claus; Maurizio Ballabio; Antonio Caretta; Carla Mucignat-Caretta
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.